In vitro diagnostics (IVD) are tests performed on the samples of blood or tissue taken from the human body to detect a wide range of diseases. These tests can monitor overall health to prevent and treat various diseases. IVD includes tests based on various techniques such as enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, polymerase chain reaction (PCR), isothermal nucleic acid amplification, and next-generation sequencing. They enable the early detection, management, and control of chronic and infectious diseases.
In Indonesia, the high prevalence of infectious and chronic diseases drives the need for early diagnosis to improve patients' quality of life. Early diagnosis of infectious diseases leads to better treatment and future care. Furthermore, early diagnosis can help medical professionals and patients make important medical decisions regarding care and support. There are many advantages of early diagnosis in the detection, prevention, and treatment of various diseases.
Indonesia has a high prevalence of infectious diseases such as tuberculosis, diarrheal disease, influenza & pneumonia, dengue, and hepatitis. These diseases are some of the leading causes of mortality in Indonesia. The incidence of these diseases is high in Indonesia and is gradually increasing. The growing prevalence of these infectious diseases has increased the utilization of In vitro diagnostics products, driving the growth of this market. According to the WHO, in 2020, Indonesia accounted for 8.4% of all estimated tuberculosis cases globally. Between January 2019 and October 2019, 110,921 cases of dengue were reported compared to 65,602 cases in 2018. Furthermore, in 2020, there were 95,971 cases of dengue fever and 663 associated deaths reported in Indonesia (Source: Indonesia's Ministry of Health, 2020).
In addition to infectious diseases, the burden of chronic diseases in Indonesia is high and rising gradually. This increase in chronic diseases can be attributed to unhealthy lifestyles, genetics, social and environmental factors, and the growing aging population, among other reasons. The aging population in Indonesia is growing rapidly. The aging population is usually highly prone to chronic diseases such as diabetes, cancer, cardiovascular diseases, Alzheimer's disease, or dementia. According to the United Nations (UN), the population aged 65 years or over in Indonesia is estimated to increase from 16.37 million in 2019 to 27.43 million by 2030, accounting for 9.2% of the country's total population in 2030. The prevalence of various chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is increasing. For instance, according to the WHO, in 2020, cancer was the fourth-leading cause of death in Indonesia. The number of new cancer cases in Indonesia is expected to increase from 396,914 in 2020 to 522,246 in 2030 (Source: International Agency for Research on Cancer).
Indonesia's Health Ministry is taking efforts to strengthen the early detection of diseases and transform the country's health system. Laboratory examination is one of the most effective and practiced testing techniques for diagnosing various infectious diseases associated with bacterial, viral, or protozoal infections. Immunoassays, biochemical characterization, polymerase chain reaction, isothermal nucleic acid amplification, and next-generation sequencing identify a comprehensive range of infectious diseases. Increasing awareness regarding the importance of early disease detection is a major factor driving Indonesia's IVD market.
In addition, public and private organizations in the country are promoting early diagnosis to prevent and eradicate mortalities caused due to infectious diseases. For instance, in February 2022, Philips Indonesia collaborated with the Philips Foundation (Netherlands) to raise awareness about the importance of early detection of breast cancer among women. Moreover, in September 2021, the International Labour Organization (ILO) collaborated with PT. Pertamina (Persero) Tbk and PT. Waskita Karya (Persero) Tbk (state-owned companies) to implement HIV self-screening to scale up HIV prevention at workplaces.
According to Meticulous Research®, the Indonesia IVD market is projected to reach $1.11 billion by 2029, at a CAGR of 10.6%.
Access Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=5352